drugset / Trial / NCT06342466
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed or previous treated systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months.
Timeline
- Start
- 2024-05-06
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |